<SEC-DOCUMENT>0001213900-25-003853.txt : 20250115
<SEC-HEADER>0001213900-25-003853.hdr.sgml : 20250115
<ACCEPTANCE-DATETIME>20250115162348
ACCESSION NUMBER:		0001213900-25-003853
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250115

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cadrenal Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001937993
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				880860746
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94027
		FILM NUMBER:		25533191

	BUSINESS ADDRESS:	
		STREET 1:		822 A1A NORTH
		STREET 2:		SUITE 300
		CITY:			PONTE VEDRA
		STATE:			FL
		ZIP:			32082
		BUSINESS PHONE:		904-300-0701

	MAIL ADDRESS:	
		STREET 1:		822 A1A NORTH
		STREET 2:		SUITE 300
		CITY:			PONTE VEDRA
		STATE:			FL
		ZIP:			32082

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MURPHY JOHN RAYMOND
		CENTRAL INDEX KEY:			0001275195
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		233 S PATTERSON AVE
		CITY:			SPRINGFIELD
		STATE:			MO
		ZIP:			65802
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001213900-23-022919</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: MURPHY JOHN RAYMOND -->
          <cik>0001275195</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>2</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001937993</issuerCik>
        <issuerName>Cadrenal Therapeutics, Inc.</issuerName>
        <issuerCusip>127636207</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>822 A1A NORTH</com:street1>
          <com:street2>Suite 306</com:street2>
          <com:city>Ponte Vedra</com:city>
          <com:stateOrCountry>FL</com:stateOrCountry>
          <com:zipCode>32082</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>John Raymond Murphy</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>53205.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>53205.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>53205.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>2.96</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>Rows 5, 7, 9 and 11 include (i) 40,986 shares of Common Stock owned by John Raymond Murphy and (ii) 12,219 shares of Common Stock issuable pursuant to options held by Mr. Murphy exercisable within 60 days.

Percentage is calculated based on 1,782,486 shares of Common Stock of the Issuer issued and outstanding as of December 31, 2024.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Cadrenal Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>822 A1A North, Suite 306, Ponte Vedra, Florida 32082</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>John Raymond Murphy (sometimes referred to as the "Reporting Person")</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>c/o Cadrenal Therapeutics, Inc.
822 A1A North, Suite 306
Ponte Vedra, Florida 32082</principalBusinessOfficeOrResidenceAddress>
        <citizenship>The Reporting Person is a citizen of the United States</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>The response set forth in row 9 and the related "Comment" on the cover page to this Amendment No. 2 are incorporated by reference into this Item 4.</amountBeneficiallyOwned>
        <classPercent>The response set forth in row 11 and the related "Comment" on the cover page to this Amendment No. 2 are incorporated by reference into this Item 4.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>The response set forth in row 5 and the related "Comment" on the cover page to this Amendment No. 2 are incorporated by reference into this Item 4.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>The response set forth in row 6 and the related "Comment" on the cover page to this Amendment No. 2 are incorporated by reference into this Item 4.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>The response set forth in row 7 and the related "Comment" on the cover page to this Amendment No. 2 are incorporated by reference into this Item 4.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>The response set forth in row 8 and the related "Comment" on the cover page to this Amendment No. 2 are incorporated by reference into this Item 4.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ss. 240.14a-11240.14.,A.-11.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>John Raymond Murphy</reportingPersonName>
      <signatureDetails>
        <signature>/s/ John Raymond Murphy</signature>
        <title>John Raymond Murphy</title>
        <date>01/15/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
